Summary
The complete sequence of the human genome and subsequent intensive searches for polymorphic variations are providing the prerequisite markers necessary to facilitate elucidation of the genetic variability in drug responses. Improvements in the sensitivity and precision of DNA microarrays permit a detailed and accurate scrutiny of the human genome. These advances have the potential to significantly improve health care management by improving disease diagnosis and targeting molecular therapy. Pharmacogenetic approaches, in limited use today, will become an integral part of therapeutic monitoring and health management, permitting patient stratification in advance of treatments, with the potential to eliminate adverse drug reactions. In this chapter, the current state of biochip technology is discussed, and recent applications in the arena of clinic diagnostics are explored.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Marton, M. J., DeRisi, J. L., Bennett, H. A., et al. (1998) Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat. Med. 4, 1293–1301.
Vilo, J., and Kivinen, K. (2001) Regulatory sequence analysis: application to the interpretation of gene expression. Eur. Neuropsychopharmacol. 11, 399–411.
Hardiman, G. Microarrays technologies 2006: an overview (2006). Pharmacogenomics. 8, 1153–1158.
Waring, J.F., Ciurlionis, R., Jolly, R.A., Heindel, M., and Ulrich, R.G. (2001) Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 120, 359–368.
Hamadeh, H.K., Amin, R.P., Paules, R.S., and Afshari, C.A. (2002) An overview of toxicogenomics. Curr. Issues Mol. Biol. 4, 45–56.
Johnson, J.A. (2001) Drug target pharmacogenomics: an overview. Am. J. Pharmacogenomics. 1, 271–281.
Kruglyak, L., and Nickerson, D.A. (2001) Variation is the spice of life. Nat. Genet. 27, 234–236.
Ensom, M.H., Chang, T.K., and Patel, P. (2001) Pharmacogenetics: the therapeutic drug monitoring of the future? Clin. Pharmacokinet. 40, 783–802.
Routledge, P.A., O'Mahony, M.S., and Woodhouse, K.W. (2004). Adverse drug reactions in elderly patients. Br. J. Clin. Pharmacol. 57, 121–126.
Lundkvist, J., and Jönsson, B. (2004) Pharmacoeconomics of adverse drug reactions. Fund. Clin. Pharmacol. 18, 275–280.
Obayashi, K., Nakamura, K., Kawana, J., et al. (2006) VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin. Pharmacol. Ther. 80, 169–178.
Eichelbaum, M., Ingelman-Sundberg, M., and Evans, W.E. (2006) Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119–137.
Desta, Z., Zhao, X., Shin, J.G., and Flockhart, D.A. (2002) Clinical significance of the cyto-chrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41, 913–958.
de Leon, J., Armstrong, S.C., and Cozza Kelly, L. (2006) Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 47, 75–85.
Bodor, M., Kelly, E.J., and Ho, R.J. (2005) Characterization of the human MDR1 gene. AAPS J. 07, E1–E5.
Southern, E.M. (1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98, 503–517.
Wallace, R.B., Shaffer, J., Murphy, R.F., Bonner, J., Hirose, T., and Itakura, K. (1979) Hybridization of synthetic oligodeoxyribonucleotides to phi chi 174 DNA: the effect of single base pair mismatch. Nucleic Acids Res. 6, 3543–3557.
Chee, M., Yang, R., Hubbell, E., et al. (1996) Accessing genetic information with high-density DNA arrays. Science. 274, 610–614.
Schena, M., Shalon, D., Davis, R.W., and Brown, P.O. (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 270, 467–470.
Bowtell, D.D.L. (1999) Options available–from start to finish for obtaining expression data by microarray. Nat. Genet. 21, 25–32.
Hardiman, G. (2004) Microarray platforms–comparisons and contrasts. Pharmacogenomics, 5, 487–502.
Wick, I., and Hardiman, G. (2005) Biochip platforms as functional genomics tools for drug discovery. Curr. Opin. Drug Discov. Dev. 8, 347–354.
Gunderson, K.L., Steemers, F.J., Lee, G., Mendoza, L.G., and Chee, M.S. (2005) A genome-wide scalable SNP genotyping assay using microarray technology. Nat. Genet. 37, 549–554.
Steemers, F.J., Chang, W., Lee, G., Barker, D.L., Shen, R., and Gunderson, K.L. (2006) Whole-genome genotyping with the single-base extension assay. Nat. Methods. 3, 31–33.
Mahant, V., Kureshy, F., Vairavan, R., and Hardiman, G. (2003) The INFINITI system–an automated multiplexing microarray platform, in Microarray Methods and Applications, vol. 16 (G. Hardiman, ed.), DNA Press, Eagleville, PA, pp. 325–328.
Kim, P., Fu, Y.K.K., Mahant, V., Kureshy, F., Hardiman, G., and Corbeil, J. (2006) The next generation of automated microarray platform for a multiplexed CYP2D6 assay, in Biochips as Pathways to Discovery, vol. 6 (A. Carmen and G. Hardiman, eds.) Taylor and Francis, New York, pp. 97–108.
Gygi, S.P., Rochon, Y., Franza, B., and Abersold, R. (1999) Correlation between protein and mRNA abundance in yeast. Mol. Cell Biol. 19, 1720–1730.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Hardiman, G. (2008). Applications of Microarrays and Biochips in Pharmacogenomics. In: Yan, Q. (eds) Pharmacogenomics in Drug Discovery and Development. Methods in Molecular Biology™, vol 448. Humana Press. https://doi.org/10.1007/978-1-59745-205-2_2
Download citation
DOI: https://doi.org/10.1007/978-1-59745-205-2_2
Publisher Name: Humana Press
Print ISBN: 978-1-58829-887-4
Online ISBN: 978-1-59745-205-2
eBook Packages: Springer Protocols